Core Viewpoint - Changchun High-tech announced a collaboration with Danish company ALK-Abelló A/S to develop and commercialize allergen-specific immunotherapy (AIT) products for house dust mites (HDM) in China, gaining exclusive rights to three of ALK's independently developed products in mainland China [1] Group 1 - Changchun High-tech's subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., will work with ALK on the AIT products [1] - The collaboration focuses on the development and commercialization of HDM allergen-specific immunotherapy products in the Chinese market [1] - The agreement includes exclusive agency rights for three ALK-developed products within mainland China [1]

Core Viewpoint - Changchun High-tech (000661.SZ) announced a collaboration with Denmark's ALK-Abelló A/S to develop and commercialize allergen-specific immunotherapy (AIT) products in China, specifically targeting house dust mites (HDM) [1] Group 1: Partnership Details - Changchun Jinsai Pharmaceutical Co., Ltd., a subsidiary of Changchun High-tech, will jointly develop and commercialize ALK's HDM allergen-specific immunotherapy products in China [1] - The collaboration grants Changchun Jinsai exclusive rights to three ALK-developed products in mainland China, including subcutaneous HDM allergen preparations (Acarizax), skin prick test kits (Acarizax), and sublingual tablets (ACARIZAX®) [1] - The partnership agreement is valid until December 31, 2039, and Changchun Jinsai will pay an upfront fee of €32.7 million for the commercialization rights [1]

Group 1 - The core point of the article is that Changchun High-tech (SZ 000661) announced a collaboration with Danish company ALK-Abelló A/S for allergen-specific immunotherapy (AIT) products during its board meeting on September 17, 2025 [1] - For the first half of 2025, the revenue composition of Changchun High-tech was as follows: 92.83% from the pharmaceutical industry, 6.81% from real estate, and 0.36% from services [1] - As of the report date, the market capitalization of Changchun High-tech was 50.5 billion yuan [1]

证券代码：000661 证券简称：长春高新 公告编号：2025-128 长春高新技术产业（集团）股份有限公司 关于子公司与丹麦 ALK-Abelló A/S 公司 达成变应原特异性免疫治疗（AIT）产品合作的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 长春高新技术产业（集团）股份有限公司（以下简称"公司"）控股子公司 ——长春金赛药业有限责任公司（以下简称"金赛药业"）与丹麦 ALK-Abelló A/S 公司（以下简称"ALK"）达成变应原特异性免疫治疗（AIT）产品合作，将在中 国联合开发并商业化 ALK 的屋尘螨（HDM）变应原特异性免疫治疗产品，并获得 ALK 自主开发的 3 款产品在中国大陆（以下简称"合作地域"）范围内的独家代 理权益。 一、许可产品基本信息 本次合作产品为 ALK 自主开发的 3 款产品，包括 2 款变应原特异性免疫治疗 产品和 1 款用于螨变应原检测的皮肤点刺试剂盒： ①屋尘螨变应原制剂（安脱达）：一款在中国已上市销售的皮下注射免疫治 疗屋尘螨变应原制剂； ②尘螨变应原舌下片（ACARIZAX®）：为全球首款被批准用于 ...

证券代码：000661 证券简称：长春高新 公告编号：2025-127 长春高新技术产业（集团）股份有限公司 第十一届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、经长春高新技术产业（集团）股份有限公司（以下简称"公司"）半数 以上董事同意，公司第十一届董事会第十三次会议于 2025 年 9 月 13 日以微信方 式发出会议通知。 2、本次董事会于 2025 年 9 月 17 日 14 时以现场结合通讯方式召开。 3、本次会议应参与表决董事 9 名，实际参与表决董事 9 名。 4、会议由董事长姜云涛先生主持，公司高级管理人员列席了本次会议。 经与会董事认真讨论，本次会议审议通过了《关于子公司与丹麦 ALK-Abelló A/S 公司达成变应原特异性免疫治疗（AIT）产品合作的议案》。 表决结果：9 票同意，0 票反对，0 票弃权。 子公司长春金赛药业有限责任公司与丹麦 ALK-Abelló A/S 公司（以下简称 "ALK"）达成变应原特异性免疫治疗（AIT）产品合作，将在中国联合开发并商 业化 ALK ...

Core Viewpoint - Changchun High-tech announced a collaboration between its subsidiary Jinsai Pharmaceutical and Denmark's ALK-Abelló A/S for the development and commercialization of allergen-specific immunotherapy (AIT) products in China, specifically targeting house dust mites (HDM) [1] Group 1: Partnership Details - Jinsai Pharmaceutical will jointly develop and commercialize ALK's HDM allergen-specific immunotherapy products in China [1] - Jinsai Pharmaceutical has secured exclusive agency rights for three products independently developed by ALK within mainland China [1] Group 2: Financial Terms - An initial payment of €32.7 million will be made by Jinsai Pharmaceutical [1] - Jinsai Pharmaceutical will pay a milestone payment of €40 million upon regulatory approval for clinical trials of the ACARIZAX sublingual tablet for adults, adolescents, and children in China [1] - Future sales performance of the products in the Chinese market may lead to additional milestone payments of €105 million [1]

Group 1 - The Biotech Index (970038) closed at 2403.29 points, down 0.55%, with a trading volume of 25.269 billion yuan and a turnover rate of 1.59% [1] - Among the index constituents, 11 stocks rose, led by Jingxin Pharmaceutical with a 2.67% increase, while 38 stocks fell, with Yaoshi Technology leading the decline at 5.11% [1] - The top ten constituents of the Biotech Index include major companies such as Mindray Medical, with a weight of 13.82% and a market cap of 290.246 billion yuan, and other notable firms like Tigermed and Changchun High-tech [1] Group 2 - The net outflow of main funds from the Biotech Index constituents totaled 1.789 billion yuan, while retail investors saw a net inflow of 1.354 billion yuan [3] - Specific stocks like Boteng Co. experienced a net inflow of 73.5819 million yuan from main funds, while others like Jiayin Pharmaceutical saw a net outflow of 4.8669 million yuan [3] - The overall trend indicates a mixed sentiment among institutional and retail investors, with significant movements in individual stocks reflecting varying levels of confidence [3]

Group 1 - The company appointed Xie Bing as the new Vice General Manager, effective until the end of the 11th Board of Directors term [1][2] - Xie Bing has a background in finance and management, previously serving as the head of the Finance Bureau and State-owned Assets Supervision and Administration Commission in Changchun New Area [2] - The appointment comes at a time when the company is facing significant pressure on its performance, with total revenue for the first half of 2025 at 6.60 billion yuan, a slight decrease of 0.54% year-on-year, and a net profit of 982.87 million yuan, down 42.85% [2][3] Group 2 - Despite the financial challenges, the company's stock price has shown resilience, closing at 123.85 yuan per share on September 16, 2025, with a year-to-date increase of 27.55% [2] - The total market capitalization reached 50.52 billion yuan, indicating sustained investor interest [2] - The company reported a significant decline in profit margins, with basic earnings per share dropping to 2.44 yuan, a decrease of 42.99% compared to the previous year [3]

Group 1 - The core viewpoint of the news is that Changchun High-tech has experienced fluctuations in stock price and trading volume, with a recent decline of 2.01% on September 16, 2023, and a total market capitalization of 50.69 billion yuan [1] - As of June 30, 2023, Changchun High-tech's revenue for the first half of 2023 was 6.603 billion yuan, a year-on-year decrease of 0.54%, while the net profit attributable to shareholders was 983 million yuan, down 42.85% year-on-year [2] - The company has a strong focus on the pharmaceutical industry, with 92.83% of its revenue coming from pharmaceuticals, while real estate and service sectors contribute 6.81% and 0.36% respectively [1][2] Group 2 - Changchun High-tech has a history of dividend payments, with a total of 4.791 billion yuan distributed since its A-share listing, and 3.259 billion yuan in the last three years [3] - The company is categorized under the pharmaceutical and biological industry, specifically in the sub-sector of biological products, and is associated with concepts such as Northeast revitalization and innovative drugs [2] - As of June 30, 2023, the number of shareholders decreased by 12.78% to 109,100, while the average circulating shares per person increased by 14.66% to 3,662 shares [2]

Core Viewpoint - Changchun High-tech Industry (Group) Co., Ltd. has revised its articles of association, which was approved at the second extraordinary general meeting of shareholders in 2025, aimed at enhancing the company's governance structure [1] Group 1: Company Overview - Changchun High-tech was established in 1993 with approval from the Changchun Economic System Reform Committee and registered with the Changchun Market Supervision Administration [2] - The company went public on December 18, 1996, with an initial issuance of 19 million shares, and currently has a registered capital of RMB 407,937,529 [2] Group 2: Governance Structure - The company has established a Party Committee and a Disciplinary Inspection Committee, with the Party Committee consisting of 9 members and the Disciplinary Committee of 7 members [3] - The governance structure includes a dual-entry and cross-appointment leadership system, with the Party Committee playing a political core role in governance [3] Group 3: Business Strategy - The company focuses on the biopharmaceutical industry as its main business, supplemented by real estate, adhering to a philosophy of creating value for users, opportunities for employees, and returns for shareholders [4] Group 4: Share Issuance and Regulations - The company issues shares in a fair and just manner, with a total of 407,937,529 ordinary shares currently outstanding [5] - There are clear regulations regarding capital increase and reduction, as well as share repurchase conditions [5] Group 5: Shareholders and Shareholder Meetings - The company maintains a shareholder register based on certificates provided by the securities registration and settlement institution, granting shareholders rights to dividends and company information [6] - The shareholder meeting is the company's authority body, with specific powers including the election of directors and approval of profit distribution plans [6] Group 6: Board of Directors - The board consists of nine directors, including a chairman and up to two vice-chairmen, with four independent directors [7] - The board is responsible for convening shareholder meetings and executing resolutions, with independent directors required to maintain their independence [7] Group 7: Senior Management - The company has one general manager and between one to six deputy general managers, with the general manager appointed by the board [8] - Senior management must adhere to the same restrictions and obligations as directors [8] Group 8: Financial Accounting and Auditing - The company has established a financial accounting system and is required to submit annual and interim reports [10] - The profit distribution policy prioritizes cash dividends, with specific conditions and ratios outlined [10] Group 9: Mergers, Divisions, and Liquidation - The company has clear procedures for mergers, divisions, capital increases, and reductions, including the need for creditor notifications [11] - Reasons for dissolution include expiration of the business term or shareholder resolution, followed by a required liquidation process [11]